"text","label","instanceType","description","uuid:ID","name","id"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","","Objective","Main objective","7d9837f0-7418-43b5-860f-e0fa26b2c4d1","OBJ1","Objective_1"
"To document the safety profile of the xanomeline TTS.","","Objective","Safety","4a3a05e6-f3b4-4e2f-9eb3-3588b4150ed8","OBJ2","Objective_2"
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","","Objective","Behaviour","5b775296-6076-46a8-948c-1ebec710eb25","OBJ3","Objective_3"
"To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","","Objective","","248fa609-ba2f-4e2f-841d-c145637c5756","OBJ4","Objective_4"
"To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","","Objective","","4aaf81f0-cd25-4827-8402-eba389f56642","OBJ5","Objective_5"
"To assess the treatment response as a function of Apo E genotype.","","Objective","","d48dd87c-9a57-4d88-8e1b-7e4d906fa661","OBJ6","Objective_6"
